AU2018359018B2 - Peptide antibiotics - Google Patents

Peptide antibiotics Download PDF

Info

Publication number
AU2018359018B2
AU2018359018B2 AU2018359018A AU2018359018A AU2018359018B2 AU 2018359018 B2 AU2018359018 B2 AU 2018359018B2 AU 2018359018 A AU2018359018 A AU 2018359018A AU 2018359018 A AU2018359018 A AU 2018359018A AU 2018359018 B2 AU2018359018 B2 AU 2018359018B2
Authority
AU
Australia
Prior art keywords
dab
group
leu
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018359018A
Other languages
English (en)
Other versions
AU2018359018A1 (en
Inventor
Bernd Becker
Mark Blaskovich
Matthew Cooper
Alysha ELLIOTT
Alejandra Gallardo-Godoy
Karl Hansford
Craig Muldoon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland UQ
Original Assignee
University of Queensland UQ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017904465A external-priority patent/AU2017904465A0/en
Application filed by University of Queensland UQ filed Critical University of Queensland UQ
Publication of AU2018359018A1 publication Critical patent/AU2018359018A1/en
Application granted granted Critical
Publication of AU2018359018B2 publication Critical patent/AU2018359018B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • C07K7/62—Polymyxins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2018359018A 2017-11-02 2018-11-02 Peptide antibiotics Active AU2018359018B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017904465A AU2017904465A0 (en) 2017-11-02 Peptide antibiotics
AU2017904465 2017-11-02
PCT/AU2018/051194 WO2019084628A1 (en) 2017-11-02 2018-11-02 Peptide antibiotics

Publications (2)

Publication Number Publication Date
AU2018359018A1 AU2018359018A1 (en) 2020-05-14
AU2018359018B2 true AU2018359018B2 (en) 2022-11-24

Family

ID=66331139

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018359018A Active AU2018359018B2 (en) 2017-11-02 2018-11-02 Peptide antibiotics

Country Status (6)

Country Link
US (1) US11279733B2 (enExample)
EP (1) EP3704135A4 (enExample)
JP (1) JP2021501783A (enExample)
CN (1) CN111527100A (enExample)
AU (1) AU2018359018B2 (enExample)
WO (1) WO2019084628A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4161481A4 (en) * 2020-06-05 2024-09-25 The Rockefeller University NATURAL BIOINFORMATIC SYNTHETIC ANTIBACTERIAL PRODUCTS AND THEIR USES
EP4330269A4 (en) * 2021-04-27 2025-07-09 Univ Rockefeller MACOLACINS AND METHODS OF USE THEREOF

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0471453A2 (en) * 1990-07-19 1992-02-19 Merck & Co. Inc. Cyclic HIV principal neutralizing determinant peptides
WO2002055543A2 (en) * 2001-01-16 2002-07-18 Univ Ramot Hybrid peptides for treatment of bacteremia and septicemia
WO2017189868A1 (en) * 2016-04-27 2017-11-02 Spero Opco Serine replacement polymyxin analogues useful as antibiotic potentiators

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3880994A (en) 1972-12-06 1975-04-29 Bristol Myers Co Antibiotic BU-1880
JPS5025795A (enExample) 1973-07-10 1975-03-18
US4341768A (en) * 1981-04-03 1982-07-27 Bristol-Myers Company Antibiotic compounds
GB2128617A (en) * 1982-10-06 1984-05-02 Martti Vaara Polypeptides for use in antibacterial therapy
US20060004185A1 (en) * 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
KR101502453B1 (ko) * 2006-08-11 2015-03-24 노던 안티바이오틱스 리미티드 폴리믹신 유도체들 및 이들의 용도
FI20085469A0 (fi) * 2008-02-08 2008-05-16 Northern Antibiotics Oy Polymyksiinijohdannaiset, joissa on lyhyt rasvahappohäntä, ja niiden käyttöjä
US9096649B2 (en) * 2008-02-08 2015-08-04 Northern Antibiotics Ltd. Polymyxin derivatives and uses thereof
WO2010130007A1 (en) 2009-05-14 2010-11-18 Monash University Antimicrobial compounds
ES2374779B1 (es) 2010-03-10 2012-12-27 Universidad De Barcelona Compuestos péptidicos útiles como agentes antibacterianos.
WO2012168820A1 (en) 2011-06-08 2012-12-13 Pfizer Inc. Polymyxin derivatives useful as antibacterial agents
KR20140091724A (ko) * 2011-11-18 2014-07-22 노박타 바이오시스템스 리미티드 폴리믹신 유도체
BR112015029309A2 (pt) 2013-05-22 2017-07-25 New Pharma Licence Holdings Ltd derivados de polimixina e seu uso em terapia de combinação junto com antibióticos diferentes
US20170073373A1 (en) * 2014-03-11 2017-03-16 New Pharma Licence Holdings Limited Polymyxin derivatives and their use in combination therapy together with different antibiotics
CN106414480B (zh) * 2014-04-01 2020-08-04 莫纳什大学 作为抗微生物化合物的多黏菌素衍生物
CN107108699A (zh) * 2014-11-26 2017-08-29 新药物许可控股有限公司 化合物
US9771394B2 (en) 2014-12-16 2017-09-26 Micurx Pharmaceuticals, Inc. Antimicrobial polymyxins for treatment of bacterial infections
JP6873043B2 (ja) 2015-03-23 2021-05-19 ポリフォー・アクチェンゲゼルシャフトＰｏｌｙｐｈｏｒ Ａｇ ベータ−ヘアピンペプチド模倣体
CA3000032A1 (en) 2015-09-29 2017-04-06 Monash University Antimicrobial polymyxin derivative compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0471453A2 (en) * 1990-07-19 1992-02-19 Merck & Co. Inc. Cyclic HIV principal neutralizing determinant peptides
WO2002055543A2 (en) * 2001-01-16 2002-07-18 Univ Ramot Hybrid peptides for treatment of bacteremia and septicemia
WO2017189868A1 (en) * 2016-04-27 2017-11-02 Spero Opco Serine replacement polymyxin analogues useful as antibiotic potentiators

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
KNIGHT, M. et al, "Inhibitory Cyclic Analogues and Chlorambucil Derivatives of Bombesin-Like Peptides", Peptides, 1995, vol. 16, no. 6, pages 1109-1115 *
PARKER, W. et al, "EM49, A NEW PEPTIDE ANTIBIOTIC II. CHEMICAL CHARACTERIZATION", The Journal of Antibiotics, 1973, vol. 26, no. 8, pages 449-456 *
SATO, Y. et al, "Novel Des-Fatty Acyl-Polymyxin B Derivatives with Pseudomonas aeruginosa-Specific Antimicrobial Activity", Chemical and Pharmaceutical Bulletin, 2011, vol. 59, no. 5, pages 597-602 *
SWANSON, P. E. et al, "Characterization of Octapeptin-Membrane Interactions Using Spin-Labeled Octapeptin", Biochemistry, 1980, vol. 19, pages 3307-3314 *
VELKOV, T. et al, "A Novel Chemical Biology Approach for Mapping of Polymyxin Lipopeptide Antibody Binding Epitopes", ACS Infectious Diseases, 2016, vol. 2, pages 341-351 *
WEINSTEIN, J. et al, "Selective Reductive Cleavage of a Threonine Peptide Bond in Polymyxin Antibiotics", Annals of the New York Academy of Science, 1986, vol. 471, pages 321-323 *

Also Published As

Publication number Publication date
EP3704135A1 (en) 2020-09-09
EP3704135A4 (en) 2022-04-27
AU2018359018A1 (en) 2020-05-14
JP2021501783A (ja) 2021-01-21
US11279733B2 (en) 2022-03-22
CN111527100A (zh) 2020-08-11
US20200361994A1 (en) 2020-11-19
WO2019084628A1 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
CA2939061C (en) Polymyxin derivatives and their use in combination therapy together with different antibiotics
KR20250021402A (ko) 헤테로환 화합물 및 이의 용도
CA2965716C (en) Crystalline form of jak kinase inhibitor bisulfate and a preparation method thereof
AU2009282478A1 (en) Flavin derivatives
UA125289C2 (uk) Композиції і способи для інгібування активності аргінази
WO2013040528A1 (en) Antimicrobial compounds
JP7402792B2 (ja) 多発性骨髄腫を治療するための新規なｕｓｐ７阻害剤
ES2745157T3 (es) Un método para la preparación, aislamiento y purificación de formas farmacéuticamente aplicables de AHU-377
AU2018359018B2 (en) Peptide antibiotics
TW202320768A (zh) 雜芳族大環醚化合物之固體形式、醫藥組成物及製備
AU2016331658A1 (en) Antimicrobial polymyxin derivative compounds
WO2017218922A2 (en) Compositions and methods for the treatment of bacterial infections
WO2021236695A1 (en) Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
WO2013190298A1 (en) 2h-imidazol-4-amine compounds and their use as bace inhibitors
CN119110724A (zh) 烟酰胺n-甲基转移酶的双环抑制剂、其组合物和用途
CA3191078A1 (en) Inhibitors of pseudomonas aeruginosa virulence factor lasb
JP2023528087A (ja) ミトコンドリア機能不全、癌、及び線維症の治療に使用されるＵＳＰ３０阻害剤としての１－（５－（２－シアノピリジン－４－イル）オキサゾール－２－カルボニル）－４－メチルヘキサヒドロピロロ［３，４－ｂ］ピロール－５（１Ｈ）－カルボニトリル
EP3087082B1 (en) Atp synthase inhibitors and steroid alkaloids and uses thereof as antimicrobial agents and as potentiators for aminoglycosides against pathogenic bacteria
US20250074945A1 (en) Antibacterial cyclopeptides targeting acinetobacter and other gram-negative pathogens
JP2023544643A (ja) バクチオ－ル誘導体、その薬学的に許容される塩及びその調製方法並びに用途
EP3958863A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases
EP4596570A1 (en) Src inhibitors and uses thereof
CA2891822A1 (en) Crystalline bortezomib process
WO2018204987A1 (en) Carbonic anhydrase inhibitors
WO2020245759A1 (en) Antibacterial compounds

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)